The European Medicines Agency and the US Food and Drug Administration are set to discuss the quality and manufacturing-related problems that sponsors face for drugs developed under the regulators’ early access programs, PRIME (priority medicines) and breakthrough therapy designation (BTD) respectively.
The discussion will take place at a workshop on Nov. 26 at the EMA's London headquarters, where the EU regulators, industry, the FDA and other international partners will try to come up with practical solutions to address quality-related issues developers face when using the (PRIME) scheme or the BTD program
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?